Mizuho analyst Graig Suvannavejh downgrades Athira Pharma (NASDAQ:ATHA) from Outperform to Neutral and lowers the price target from $5 to $0.5.
- Headlines
- Mizuho Downgrades Athira Pharma to Neutral, Lowers Price Target to $0.5
Mizuho Downgrades Athira Pharma to Neutral, Lowers Price Target to $0.5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
20:23
Is Shenzhen's real estate market experiencing a "buy one, get one free" promotion again? Industry experts say that compared to directly lowering prices, "buy one, get one free" is more beneficial for clearing inventory.
20:23
According to the MasterCard Consumer report, from November 1 to December 24, retail sales in the USA (excluding Autos) grew by 3.8% year-on-year.
MA+1.28%
20:19
After RAYMOND JAMES upgraded the rating from outperform Large Cap to Strong Buy, EVERQUOTE's stock price rose 4.2% in pre-market trading.
EVER+3.50%